New pharmacological approaches for obesity management

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Nature Reviews Endocrinology

• Publication date

  2013-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrendo.2013.113PMID 23752772
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2).

  2013cited by this paper
• A history of drugs on the weight list

  2012cited by this paper
• Appetite regulation and weight control: the role of gut hormones

  2012cited by this paper
• The medical care costs of obesity: an instrumental variables approach.

  2012cited by this paper
• Randomized Placebo‐Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM‐DM Study

  2012cited by this paper
• Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.

  2011cited by this paper
• A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.

  2011cited by this paper
• Naltrexone Depot Formulations for Opioid and Alcohol Dependence: A Systematic Review

  2011cited by this paper
• Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR‐BMOD Trial

  2011cited by this paper
• Hypothalamic opioid-melanocortin appetitive balance and addictive craving.

  2011cited by this paper
• Topiramate-induced weight loss: a review.

  2011cited by this paper
• Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)

  2011cited by this paper
• Long-term persistence of hormonal adaptations to weight loss.

  2011cited by this paper
• Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity

  2011cited by this paper
• Efficacy and safety of topiramate on weight loss: a meta‐analysis of randomized controlled trials

  2011cited by this paper
• Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

  2011cited by this paper
• Combination therapy with naltrexone and bupropion for obesity

  2011cited by this paper
• Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

  2010cited by this paper
• Effects of experimental weight perturbation on skeletal muscle work efficiency, fuel utilization, and biochemistry in human subjects.

  2010cited by this paper
• Multicenter, placebo-controlled trial of lorcaserin for weight management.

  2010cited by this paper
• Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for ‘sick fat’ and metabolic disease

  2009cited by this paper
• Rational Design of a Combination Medication for the Treatment of Obesity

  2009cited by this paper
• Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.

  2009cited by this paper
• Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity

  2009cited by this paper
• Long-term persistence with orlistat and sibutramine in a population-based cohort

  2007cited by this paper
• Serotonin 2C Receptor Agonists Improve Type 2 Diabetes via Melanocortin-4 Receptor Signaling Pathways

  2007cited by this paper
• Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up.

  2007cited by this paper
• Effects on Weight Reduction and Safety of Short-Term Phentermine Administration in Korean Obese People

  2006cited by this paper
• Topiramate in pregnancy

  2006cited by this paper
• Central nervous system control of food intake and body weight

  2006cited by this paper
• Drug treatment of obesity.

  2005cited by this paper
• Anatomy and regulation of the central melanocortin system

  2005cited by this paper
• Serotonin receptor ligands and the treatment of obesity.

  2004cited by this paper
• An integrated method to determine meaningful changes in health-related quality of life.

  2004cited by this paper
• A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects

  2004cited by this paper
• A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects

  2004cited by this paper
• Health-related quality of life in obese outpatients losing weight with very-low-energy diet and behaviour modification—a 2-y follow-up study

  2003cited by this paper
• Invited review: Aging and energy balance.

  2003cited by this paper
• Health-related quality of life in obese outpatients losing weight with very-low-energy diet and behaviour modification: a 2-y follow-up study

  2003cited by this paper
• Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials

  2002cited by this paper
• Central nervous system control of food intake

  2000cited by this paper
• Inaccurate information on quetiapine.

  1998cited by this paper
• Bupropion sustained release and smoking cessation.

  1998cited by this paper
• Valvular heart disease associated with fenfluramine-phentermine.

  1997cited by this paper
• Appetite Suppressants

  1992cited by this paper
• Appetite suppressants. A review.

  1992cited by this paper
• Naltrexone and human eating behavior: a dose-ranging inpatient trial in moderately obese men.

  1985cited by this paper
• A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination.

  1984cited by this paper
• Review of bupropion.

  1983cited by this paper
• Comparison of continuous and intermittent anorectic therapy in obesity.

  1968cited by this paper

• Graphene-cobalt hexacyanoferrate modified sensor doped with molecularly imprinted polymer for selective potentiometric determination of bupropion

  2025cites this paper
• Identification of a neural basis for energy expenditure in the mouse arcuate hypothalamus.

  2025cites this paper
• Adipose tissue-targeted drug delivery for treating obesity: current opportunities and challenges

  2025cites this paper
• An eco-friendly smartphone based HPTLC method versus conventional densitometric one for determination of Naltrexone and Bupropion

  2024cites this paper
• Mechanism of Action and Structure–Activity Relationships of Tetracyclic Small Molecules Acting as Universal Positive Allosteric Modulators of the Cholecystokinin Receptor

  2023cites this paper
• Phentermine involvement in fatal drug overdoses in Tennessee, 2019-2022.

  2023cites this paper
• Anti-obesity weight loss medications: Short-term and long-term use.

  2022cites this paper
• Exosomal miR‐122 promotes adipogenesis and aggravates obesity through the VDR/SREBF1 axis

  2022cites this paper
• Fundamental Factors of Overweight, Obesity, and Metabolic Syndromein Cardiovascular Disease (Key Points that HealthcareProviders, Public Health Policymakers, and the General Public ShouldKnow about the CVD-Obesity Connection)

  2020cites this paper
• Incremental cost‐effectiveness of evidence‐based non‐surgical weight loss strategies

  2019cites this paper
• Obesity and the Effects of Weight Reduction: A Spotlight on Women with Hormone Receptor-Positive Breast Cancer and Heart Disease

  2019cites this paper
• In vivo measurement of enhanced agouti-related peptide release in the paraventricular nucleus of the hypothalamus through Gs activation of agouti-related peptide neurons

  2019cites this paper
• Ginsenoside Rg1 inhibits dietary-induced obesity and improves obesity-related glucose metabolic disorders

  2018cites this paper
• Current Weight Management Approaches Used by Primary Care Providers in Six Multidisciplinary Healthcare Settings in Ontario

  2018cites this paper
• Medical Management of Obesity

  2018cites this paper
• Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development

  2017cites this paper
• Comparison of the mixed-meal stimulated gut hormone secretion profile after classical gastric bypass and the long biliopancreatic limb variant.

  2017cites this paper
• Lorcaserin Administration Decreases Activation of Brain Centers in Response to Food Cues and These Emotion- and Salience-Related Changes Correlate With Weight Loss Effects: A 4-Week-Long Randomized, Placebo-Controlled, Double-Blind Clinical Trial

  2016cites this paper
• AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.

  2016cites this paper
• Current and Emerging Treatment Options in Diabetes Care.

  2016cites this paper
• Intestinal removal of free fatty acids from hosts by Lactobacilli for the treatment of obesity

  2016cites this paper
• Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis

  2016cites this paper
• Cholecystokinin-induced satiety, a key gut servomechanism that is affected by the membrane microenvironment of this receptor.

  2016cites this paper
• Fatty Acid Transport Proteins: Targeting FATP2 as a Gatekeeper Involved in the Transport of Exogenous Fatty Acids.

  2016cites this paper
• Pharmacological Management of Obesity in Patients with Type 2 Diabetes: An Update

  2016cites this paper
• Inequalities in access to bariatric surgery in Canada

  2016cites this paper
• Subcutaneous liraglutide reduces weight and improves metabolic control in obese participants

  2015influential citation
• ANTI-OBESITY PHARMACOTHERAPY AND THE POTENTIAL FOR PREVENTING PROGRESSION FROM PREDIABETES TO TYPE 2 DIABETES.

  2015cites this paper
• Pharmacotherapy for the treatment of obesity.

  2015cites this paper
• Gremlin 2 inhibits adipocyte differentiation through activation of Wnt/β-catenin signaling.

  2015cites this paper
• Alternative Treatments for Weight Loss: Safety/Risks and Effectiveness of Anti-Obesity Medicinal Plants

  2015cites this paper
• Obesity medications: what does the future look like?

  2015cites this paper
• The long‐term effect of energy restricted diets for treating obesity

  2015cites this paper
• Antiobesity strategy targets energy economy safeguards.

  2015cites this paper
• RP-HPLC AND SPECTROPHOTOMETRIC METHODS FOR THE SIMULTANEOUS ESTIMATION OF BUPROPION HCl AND NALTREXONE HCl

  2015cites this paper
• Peptides in metabolic diseases

  2015cites this paper
• Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice

  2015cites this paper
• Current and Emerging Treatment Options

  2015cites this paper
• Next Generation of Weight Management Medications: Implications for Diabetes and CVD Risk

  2015cites this paper
• Obesity Education Strategies for Cancer Prevention in Women’s Health

  2015cites this paper
• Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment

  2015influential citation
• Health Benefits of Long-Term Weight-Loss Maintenance.

  2015cites this paper
• Forecasting Adult Weight Status Trends in Canada with Longitudinal Population-based Data

  2015cites this paper
• Assessment of Body Composition

  2015cites this paper
• Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate

  2014cites this paper
• Pharmacological management of obesity: Past, present and future

  2014cites this paper
• Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date

  2014cites this paper
• Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes.

  2014cites this paper
• Targeting Adipose Tissue Lipid Metabolism to Improve Glucose Metabolism in Cardiometabolic Disease

  2014cites this paper
• New centrally acting agents for appetite control: from biological mechanisms to clinical efficacy

  2014cites this paper
• Pharmacological interventions for reducing weight gain in schizophrenia

  2014cites this paper
• Pharmakologische Ansätze in der Adipositastherapie

  2014cites this paper
• Regulation of obesity and insulin resistance by nitric oxide.

  2014cites this paper
• The anti-obesogenic effects of nitric oxide.

  2014cites this paper
• Obesity and outpatient rehabilitation using mobile technologies: the potential mHealth approach

  2014cites this paper
• Peripheral targets in obesity treatment: a comprehensive update

  2014cites this paper
• Anti-obesity activity of hen egg anti-lipase immunoglobulin yolk, a novel pancreatic lipase inhibitor

  2013cites this paper